WO2021036294A1 - Vaginal acid-base buffer gel and preparation method - Google Patents

Vaginal acid-base buffer gel and preparation method Download PDF

Info

Publication number
WO2021036294A1
WO2021036294A1 PCT/CN2020/085844 CN2020085844W WO2021036294A1 WO 2021036294 A1 WO2021036294 A1 WO 2021036294A1 CN 2020085844 W CN2020085844 W CN 2020085844W WO 2021036294 A1 WO2021036294 A1 WO 2021036294A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
base
vaginal
purified water
sodium
Prior art date
Application number
PCT/CN2020/085844
Other languages
French (fr)
Chinese (zh)
Inventor
魏民
黄波
贾芳
刘淑敏
Original Assignee
南京天朗制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京天朗制药有限公司 filed Critical 南京天朗制药有限公司
Publication of WO2021036294A1 publication Critical patent/WO2021036294A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina

Definitions

  • the invention belongs to the field of pharmacy, and specifically relates to a vaginal acid-base buffer gel and a preparation method.
  • vaginal pH of women of normal childbearing age is between 3.8 and 4.5. This acidic environment is formed because of the glycogen of the vaginal epithelial tissue and the presence of lactobacilli in the vaginal flora of women of childbearing age. Lactobacillus uses glycogen to produce lactic acid to maintain the acidic environment of the vagina while inhibiting the growth of pathogens, which is called vaginal self-purification. Lactobacillus is also called vagina guard.
  • vaginal pH can be the cause of vaginal disease, or it can be the result of disease. Maintaining a normal vaginal pH is an important guarantee for vaginal health; there are many microorganisms in the normal vagina, but due to the formation of the ecological balance between these microorganisms in the vagina, it does not cause disease. Once the ecological balance is broken or foreign pathogens invade, That is, inflammation occurs. Lactobacillus, vaginal pH, and estrogen are the most important factors in maintaining the ecological balance of the vagina;
  • buffer gels are currently used for treatment, but the existing buffer gels have the following shortcomings: 1.
  • the appearance of the product gel is soft, not shaped, cannot stay in the body for a long time, and is easy to flow out and pollute. Underwear; 2.
  • the product is not effective in use, and the auxiliary treatment effect of vaginitis is quite poor; 3.
  • Patients with damaged vaginal mucosa have a temporary irritation and pain during use; 4.
  • the price is too high; the performance of the product is relatively high Poor; the preparation process takes a long time, which easily causes the product to be easily oxidized and discolored;
  • the product prepared by the present invention can effectively adjust the vaginal environment of original inflammation, remove vaginal odor, and improve symptoms such as increased vaginal discharge and itching.
  • the purpose of the present invention is to provide a vaginal acid-base buffer gel and a preparation method.
  • the product prepared by the present invention can effectively adjust the vaginal environment of original inflammation, remove vaginal odor, and improve symptoms such as increased vaginal discharge and itching.
  • a vaginal acid-base buffering gel which is characterized in that it is composed of the following mass components: oil phase base 1% to 39%, water phase base 60% to 99%, acid base regulator 0.001% to 2% and Bacteriostatic agent 0.05% to 5%;
  • the oil phase-based component is a mixture of one or more of white petrolatum, liquid paraffin, glyceryl behenate, Span, Tween, glycerin or propylene glycol;
  • the water-based components are hydroxypropyl methyl cellulose, carbomer, sodium carboxymethyl cellulose, polycarbophil, polyethylene glycol, azone, gelatin or a mixture of one or more of purified water ;
  • the acid-base regulator is a mixture of one or more of citric acid, sodium citrate, sodium hydroxide, hydrochloric acid, triethanolamine, boric acid, borax, sodium dihydrogen phosphate or disodium hydrogen phosphate;
  • the bacteriostatic agent is a mixture of one or more of benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, sorbic acid, potassium sorbate or parabens.
  • the formula is 39% oil phase base, 60% water phase base, 0.6% acid-base regulator and 0.4% bacteriostatic agent;
  • the oil phase base component is composed of white petrolatum, Span 60 and Tween 80;
  • the water phase base component is composed of hydroxypropyl methyl cellulose and purified water
  • Acid-base regulator is composed of sodium citrate
  • the bacteriostatic agent is composed of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
  • 39% of the oil phase base is composed of 36% white petrolatum, 1% Span 60 and 2% Tween 80;
  • 60% of the water phase base is composed of 1% hydroxypropyl methylcellulose, 1% polycarbophil and 58% purified water;
  • the acid-base regulator is composed of 0.6% sodium citrate
  • the antibacterial agent 0.4% is composed of 0.3% methyl p-hydroxybenzoate and 0.1% propyl p-hydroxybenzoate.
  • a method for preparing vaginal acid-base buffer gel the steps are as follows:
  • the sterilization time is 30 to 60 minutes.
  • steps S3 and S5 a homogenizer is used for mixing and stirring.
  • Vaginal acid-base buffer gel is a polymer gel product.
  • a process of polymer material swelling is required.
  • the time of polymer swelling often determines the success or failure of the finished product; in the traditional process During the preparation process, it is necessary to swell the polymer materials and other raw materials with purified water one day in advance, and then mix and reprocess the materials the next day. This greatly increases the probability of contamination of the sample and also causes oxidation reaction between the gel and the stainless steel container.
  • polycarbophil is added to the traditional formula, and the molecular chain of polycarbophil has many hydroxyl groups, which endows the gel product with excellent acid-base buffering capacity and unique bioadhesiveness, which can promote activity
  • the ingredients are transported to various mucosal surfaces and pressed onto the damaged mucosal surface with small wounds in the form of spherical molecules, which has the effect of relieving pain and hemostasis; and polycarbophil has significant water absorption and water retention, and can absorb its own weight of 600 It swells but does not dissolve, forming a hydrogel with high water content.
  • This can solve the problem of the formation of the vaginal acid-base buffer gel.
  • the gel can fit the vaginal mucosa 100% in an all-round way, is not easy to undercut, prolongs the time the product stays in the body, and enhances the product's auxiliary treatment effect.
  • a vaginal acid-base buffer gel comprising the following quality components: 19% oil phase base is composed of 16% white petrolatum, 1% Span 60 and 2% Tween 80;
  • 80% of the aqueous phase is composed of 1% carbomer, 1% polycarbophil, and 78% purified water;
  • Acid-base regulator is composed of 0.6% sodium hydroxide
  • the bacteriostatic agent consists of 0.4% benzalkonium bromide.
  • vaginal acid-base buffer gel The preparation method of a vaginal acid-base buffer gel is as follows:
  • a vaginal acid-base buffer gel including the following quality components: 39% of the oil phase base is composed of 36% white petrolatum, 1% Span 60 and 2% Tween 80;
  • 60% of the water phase base is composed of 1% hydroxypropyl methylcellulose, 1% polycarbophil, and 58% purified water;
  • Acid-base regulator is composed of 0.6% sodium citrate
  • the antibacterial agent 0.4% is composed of 0.3% methyl p-hydroxybenzoate and 0.1% propyl p-hydroxybenzoate.
  • a preparation method of vaginal acid-base buffer gel is as follows:
  • vaginal acid-base buffer gel including the following mass components: oil phase base 29% composed of white petrolatum 26%, 1% Span 60 and 2% Tween 80 composition;
  • 70% of the water phase base is composed of 1% carbomer, 1% polycarbophil, and 68% purified water;
  • the acid-base regulator 0.6% is composed of 0.3% sodium citrate and 0.3% sodium hydroxide
  • the antibacterial agent 0.4% consists of benzalkonium chloride.
  • vaginal acid-base buffer gel In the setting of the pH value of the vaginal acid-base buffer gel, attention should be paid to establishing the micro-balance of the vaginal environment.
  • the setting of pH value needs to break the conventional neutrality, and choose a pH value (4.0 to 5.5) that is neutral and acidic, so that the gel can effectively regulate the vaginal environment of the original inflammation, remove vaginal odor, and improve Symptoms such as increased vaginal discharge and itching;
  • the A1, A2, and A3 groups use the original prescription product vaginal pH buffer gel according to the instructions;
  • the B1, B2 and B3 groups use the formulas of Example 1, Example 2, and Example 3 respectively according to the instructions.
  • the vagina pH buffering gel, the corresponding drugs are used continuously, and once a day, 14 days after the drug, the statistics are as follows:

Abstract

A vaginal acid-base buffer gel and a preparation method, the gel consisting of the following components by mass: 1%-39% of an oil phase base, 60%-99% of a water phase base, 0.001%-2% of a pH regulator and 0.05%-5% of a bacteriostat, wherein the oil phase base is white petrolatum or liquid paraffin or glyceryl behenate or Span or Tween or glycerol or propylene glycol; the water phase base is hydroxypropyl methylcellulose or carbomer or sodium carboxymethylcellulose or polycarbophil or polyethylene glycol or azone or gelatin or purified water; the pH regulator is citric acid or sodium citrate or sodium hydroxide or hydrochloric acid or triethanolamine or boric acid or borax or sodium dihydrogen phosphate or disodium hydrogen phosphate; and the bacteriostat is benzoic acid or sodium benzoate or benzyl alcohol or benzalkonium bromide or benzalkonium chloride or sorbic acid or potassium sorbate or nipalgin. The prepared product may effectively regulate the original vaginal environment of inflammation, remove vaginal odor and relieve symptoms such as increased vaginal secretions or itching.

Description

一种阴道酸碱缓冲凝胶及制备方法Vaginal acid-base buffer gel and preparation method 技术领域Technical field
本发明属于制药领域,具体涉及一种阴道酸碱缓冲凝胶及制备方法。The invention belongs to the field of pharmacy, and specifically relates to a vaginal acid-base buffer gel and a preparation method.
背景技术Background technique
正常生育年龄妇女的阴道pH在3.8至4.5,这种酸性环境形成是因为阴道上皮组织糖原,以及育龄妇女阴道菌群中的乳酸杆菌的存在。乳酸杆菌利用糖原产生乳酸以维持阴道酸性环境,同时抑制病原体生长,称为阴道自净作用。乳酸杆菌也被称为阴道卫士。The vaginal pH of women of normal childbearing age is between 3.8 and 4.5. This acidic environment is formed because of the glycogen of the vaginal epithelial tissue and the presence of lactobacilli in the vaginal flora of women of childbearing age. Lactobacillus uses glycogen to produce lactic acid to maintain the acidic environment of the vagina while inhibiting the growth of pathogens, which is called vaginal self-purification. Lactobacillus is also called vagina guard.
阴道pH值的改变可以是阴道致病的原因,也可以是致病后的结果。维持正常的阴道pH是阴道健康的重要保证;正常阴道内有许多微生物存在,但由于阴道内这些微生物之间生态平衡形成,所以并不致病,一旦生态平衡被打破或外源性病原体侵入,即导致炎症发生,在维持阴道生态平衡中乳酸杆菌、阴道pH值、雌激素是最重要的构成因素;The change in vaginal pH can be the cause of vaginal disease, or it can be the result of disease. Maintaining a normal vaginal pH is an important guarantee for vaginal health; there are many microorganisms in the normal vagina, but due to the formation of the ecological balance between these microorganisms in the vagina, it does not cause disease. Once the ecological balance is broken or foreign pathogens invade, That is, inflammation occurs. Lactobacillus, vaginal pH, and estrogen are the most important factors in maintaining the ecological balance of the vagina;
针对上述疾病或症状,现多采用缓冲凝胶进行治疗,但现有的缓冲凝胶具备以下不足:1、产品凝胶外观性状较软,不成形,不能在体内长时间逗留,易流出,污染内衣裤;2、产品在使用效果不明显,辅助治疗阴道炎效果蛮差;3、有破损阴道粘膜的患者在使用过程中具有一过性的刺激痛感;4、价格虚高;产品使用性能较差;配制过程时间较长,容易导致产品易氧化、变色;For the above-mentioned diseases or symptoms, buffer gels are currently used for treatment, but the existing buffer gels have the following shortcomings: 1. The appearance of the product gel is soft, not shaped, cannot stay in the body for a long time, and is easy to flow out and pollute. Underwear; 2. The product is not effective in use, and the auxiliary treatment effect of vaginitis is quite poor; 3. Patients with damaged vaginal mucosa have a temporary irritation and pain during use; 4. The price is too high; the performance of the product is relatively high Poor; the preparation process takes a long time, which easily causes the product to be easily oxidized and discolored;
针对上述不足,现需求一种阴道酸碱缓冲凝胶及制备方法,本发明制备的产品可有效的调节原有炎症的阴道环境,去除阴道异味,改善阴道分泌物增多、瘙痒等症状。In view of the above shortcomings, there is a need for a vaginal acid-base buffer gel and a preparation method. The product prepared by the present invention can effectively adjust the vaginal environment of original inflammation, remove vaginal odor, and improve symptoms such as increased vaginal discharge and itching.
发明内容Summary of the invention
本发明的目的提供一种阴道酸碱缓冲凝胶及制备方法,本发明制备的产品可有效的调节原有炎症的阴道环境,去除阴道异味,改善阴道分泌物增多、瘙痒等症状。The purpose of the present invention is to provide a vaginal acid-base buffer gel and a preparation method. The product prepared by the present invention can effectively adjust the vaginal environment of original inflammation, remove vaginal odor, and improve symptoms such as increased vaginal discharge and itching.
本发明提供了如下的技术方案:The present invention provides the following technical solutions:
一种阴道酸碱缓冲凝胶,其特征在于:由以下质量组分的物质组成,油相基1%至39%、水相基60%至99%、酸碱调节剂0.001%至2%和抑菌剂0.05%至5%;A vaginal acid-base buffering gel, which is characterized in that it is composed of the following mass components: oil phase base 1% to 39%, water phase base 60% to 99%, acid base regulator 0.001% to 2% and Bacteriostatic agent 0.05% to 5%;
所述油相基组分为白凡士林、液体石蜡、山嵛酸甘油酯、司盘、吐温、甘油或丙二醇中一种或多种的混合物;The oil phase-based component is a mixture of one or more of white petrolatum, liquid paraffin, glyceryl behenate, Span, Tween, glycerin or propylene glycol;
水相基组分为羟丙基甲基纤维素、卡波姆、羧甲基纤维素钠、聚卡波非、聚乙二醇、氮酮、明胶或纯化水中的一种或多种的混合物;The water-based components are hydroxypropyl methyl cellulose, carbomer, sodium carboxymethyl cellulose, polycarbophil, polyethylene glycol, azone, gelatin or a mixture of one or more of purified water ;
酸碱调节剂为枸橼酸、枸橼酸钠、氢氧化钠、盐酸、三乙醇胺、硼酸、硼砂、磷酸二氢钠或磷酸氢二钠的一种或多种的混合物;The acid-base regulator is a mixture of one or more of citric acid, sodium citrate, sodium hydroxide, hydrochloric acid, triethanolamine, boric acid, borax, sodium dihydrogen phosphate or disodium hydrogen phosphate;
抑菌剂为苯甲酸、苯甲酸钠、苯甲醇、苯扎溴铵、苯扎氯铵、山梨酸、山梨酸钾或尼泊金类的一种或多种的混合物。The bacteriostatic agent is a mixture of one or more of benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, sorbic acid, potassium sorbate or parabens.
优选的,配方为油相基39%、水相基60%、酸碱调节剂0.6%和抑菌剂0.4%;Preferably, the formula is 39% oil phase base, 60% water phase base, 0.6% acid-base regulator and 0.4% bacteriostatic agent;
所述油相基组分由白凡士林、司盘60和吐温80组成;The oil phase base component is composed of white petrolatum, Span 60 and Tween 80;
水相基组分由羟丙基甲基纤维素和纯化水组成;The water phase base component is composed of hydroxypropyl methyl cellulose and purified water;
酸碱调节剂由枸橼酸钠组成;Acid-base regulator is composed of sodium citrate;
抑菌剂由对羟基苯甲酸甲酯、对羟基苯甲酸丙酯组成。The bacteriostatic agent is composed of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
优选的,油相基39%由组分白凡士林36%、1%的司盘60和2%的吐温80组成;Preferably, 39% of the oil phase base is composed of 36% white petrolatum, 1% Span 60 and 2% Tween 80;
水相基60%由组分为1%的羟丙基甲基纤维素、1%的聚卡波非和纯化水58%组成;60% of the water phase base is composed of 1% hydroxypropyl methylcellulose, 1% polycarbophil and 58% purified water;
酸碱调节剂由0.6%的枸橼酸钠组成;The acid-base regulator is composed of 0.6% sodium citrate;
抑菌剂0.4%由对羟基苯甲酸甲酯0.3%和对羟基苯甲酸丙酯0.1%组成。The antibacterial agent 0.4% is composed of 0.3% methyl p-hydroxybenzoate and 0.1% propyl p-hydroxybenzoate.
一种阴道酸碱缓冲凝胶制备方法,其步骤如下:A method for preparing vaginal acid-base buffer gel, the steps are as follows:
S1、称取适量枸橼酸钠,加入适量纯化水,搅拌溶解备用;S1. Weigh an appropriate amount of sodium citrate, add an appropriate amount of purified water, stir and dissolve for later use;
S2、按原料配比,将一半的纯化水注入乳化机组配料罐内,然后将纯化水加热至100℃进行灭菌,并冷确至80℃后,并按配比向乳化机组配料罐内依次加入白凡士林、司盘60、吐温80、聚卡波非、羟丙基甲基纤维素和白凡士林,边搅拌边溶胀,时间为1小时;S2. According to the ratio of raw materials, inject half of the purified water into the batching tank of the emulsification unit, then heat the purified water to 100°C for sterilization, and cool it to 80°C, and then add it to the batching tank of the emulsification unit according to the ratio. White Vaseline, Span 60, Tween 80, Polycarbophil, Hydroxypropyl Methyl Cellulose and White Vaseline, swell while stirring for 1 hour;
S3、按配比,向乳化机组配料罐内加入抑菌剂,搅拌30分钟;S3. According to the ratio, add the antibacterial agent to the batching tank of the emulsification unit, and stir for 30 minutes;
S4、开启真空,开启冷却水,对乳化机组配料罐进行冷却,当温度降至45℃时,关闭冷却水;S4. Turn on the vacuum and turn on the cooling water to cool the batching tank of the emulsification unit. When the temperature drops to 45°C, turn off the cooling water;
S5、按配比,向乳化机组配料罐内加入配制好的枸橼酸钠溶液,按配比加纯化水至足量,搅拌30分钟,制得本品。S5. Add the prepared sodium citrate solution to the batching tank of the emulsification unit according to the ratio, add purified water to sufficient amount according to the ratio, and stir for 30 minutes to prepare this product.
优选的,S2步骤中,灭菌时间为30至60分钟。Preferably, in step S2, the sterilization time is 30 to 60 minutes.
优选的,S3和S5步骤中,全部采用均质机进行混合搅拌。Preferably, in steps S3 and S5, a homogenizer is used for mixing and stirring.
本发明的有益效果:The beneficial effects of the present invention:
(1)阴道酸碱缓冲凝胶为高分子凝胶类产品,在该类产品的工艺配制过程中需要有高分子材料溶胀的过程,高分子溶胀的时间往往决定了成品的成败;在传统工艺配制过程中,需要提前一天用纯化水溶胀高分子材料等原料,第二天再进行物料混合与再加工,如此大大增加了样品的染菌几率,还会造成凝胶与不锈钢容器发生氧化反应,而本生产工艺通过加入司盘60和吐温80,将原溶胀时间约8小时缩短至1小时,配制样品时间由原有的两天缩短至一天,可有效改善现有工艺的问题,且可大大提高生产效率。(1) Vaginal acid-base buffer gel is a polymer gel product. In the process of preparation of this type of product, a process of polymer material swelling is required. The time of polymer swelling often determines the success or failure of the finished product; in the traditional process During the preparation process, it is necessary to swell the polymer materials and other raw materials with purified water one day in advance, and then mix and reprocess the materials the next day. This greatly increases the probability of contamination of the sample and also causes oxidation reaction between the gel and the stainless steel container. In this production process, by adding Span 60 and Tween 80, the original swelling time is shortened from about 8 hours to 1 hour, and the sample preparation time is shortened from the original two days to one day, which can effectively improve the problems of the existing process and can Greatly improve production efficiency.
(2)本制备工艺在传统的配方中加入聚卡波非,而聚卡波非分子链上有众多的羟基,赋予凝胶产品优异的酸碱缓冲能力和独一无二的生物黏附性,可促进活性成分输送到各种黏膜表面,以球状分子形态压力贴合在有微小创面的破损黏膜表面,起到止痛止血的效果;且聚卡波非具有显著的吸水能力和保水性,能吸收自身重量600倍的水分,溶胀而不溶解,形成高含水率的水凝胶。这可以解决阴道酸碱缓冲凝胶的成形的问题,凝胶可100%全方位贴合阴道粘膜,不易下划,延长产品留在体内的时间,增强产品辅助治疗的效果。(2) In this preparation process, polycarbophil is added to the traditional formula, and the molecular chain of polycarbophil has many hydroxyl groups, which endows the gel product with excellent acid-base buffering capacity and unique bioadhesiveness, which can promote activity The ingredients are transported to various mucosal surfaces and pressed onto the damaged mucosal surface with small wounds in the form of spherical molecules, which has the effect of relieving pain and hemostasis; and polycarbophil has significant water absorption and water retention, and can absorb its own weight of 600 It swells but does not dissolve, forming a hydrogel with high water content. This can solve the problem of the formation of the vaginal acid-base buffer gel. The gel can fit the vaginal mucosa 100% in an all-round way, is not easy to undercut, prolongs the time the product stays in the body, and enhances the product's auxiliary treatment effect.
具体实施方式detailed description
实施例1:Example 1:
一种阴道酸碱缓冲凝胶,包括以下质量组分的物质:油相基19%由组分白凡士林16%、1%的司盘60和2%的吐温80组成;A vaginal acid-base buffer gel, comprising the following quality components: 19% oil phase base is composed of 16% white petrolatum, 1% Span 60 and 2% Tween 80;
水相基80%由组分为1%的卡波姆、1%的聚卡波非、和纯化水78%组成;80% of the aqueous phase is composed of 1% carbomer, 1% polycarbophil, and 78% purified water;
酸碱调节剂由0.6%氢氧化钠组成;Acid-base regulator is composed of 0.6% sodium hydroxide;
抑菌剂由0.4%苯扎溴铵组成。The bacteriostatic agent consists of 0.4% benzalkonium bromide.
一种阴道酸碱缓冲凝胶制备方法如下:The preparation method of a vaginal acid-base buffer gel is as follows:
S1、称取适量氢氧化钠配制成0.5mol/L的氢氧化钠溶液备用;S1. Weigh an appropriate amount of sodium hydroxide to prepare a 0.5mol/L sodium hydroxide solution for later use;
S2、按原料配比,将一半的纯化水注入乳化机组配料罐内,然后将纯化水加热至100℃进行灭菌60分钟,并冷确至80℃后,并按配比向乳化机组配料罐内依次加入司盘60、吐温80、聚卡波非、卡波姆和白凡士林,采用均质机边搅拌边溶胀,时间为1小时;S2. According to the ratio of raw materials, inject half of the purified water into the emulsification unit batching tank, then heat the purified water to 100°C for sterilization for 60 minutes, and cool it to 80°C, and send it to the emulsification unit batching tank according to the ratio Add Span 60, Tween 80, Polycarbophil, Carbomer and White Vaseline in sequence, and swell while stirring with a homogenizer for 1 hour;
S3、按配比,向乳化机组配料罐内加入抑菌剂,搅拌30分钟;S3. According to the ratio, add the antibacterial agent to the batching tank of the emulsification unit, and stir for 30 minutes;
S4、开启真空,开启冷却水,对乳化机组配料罐进行冷却,当温度降至45℃时,关闭冷却水;S4. Turn on the vacuum and turn on the cooling water to cool the batching tank of the emulsification unit. When the temperature drops to 45°C, turn off the cooling water;
S5、按配比,向乳化机组配料罐内加入配制好的0.5mol/L的氢氧化钠溶液,按配比加纯化水至足量,采用均质机搅拌30分钟,制得本品。S5. According to the proportion, add the prepared 0.5mol/L sodium hydroxide solution to the emulsification unit batching tank, add purified water to sufficient amount according to the proportion, and stir for 30 minutes with a homogenizer to prepare this product.
实施例2:Example 2:
一种阴道酸碱缓冲凝胶,包括以下质量组分的物质:油相基39%由组分白凡士林36%、1%的司盘60和2%的吐温80组成;A vaginal acid-base buffer gel, including the following quality components: 39% of the oil phase base is composed of 36% white petrolatum, 1% Span 60 and 2% Tween 80;
水相基60%由组分为1%的羟丙基甲基纤维素、1%的聚卡波非、和纯化水58%组成;60% of the water phase base is composed of 1% hydroxypropyl methylcellulose, 1% polycarbophil, and 58% purified water;
酸碱调节剂由0.6%枸橼酸钠组成;Acid-base regulator is composed of 0.6% sodium citrate;
抑菌剂0.4%由对羟基苯甲酸甲酯0.3%和对羟基苯甲酸丙酯0.1%组成。The antibacterial agent 0.4% is composed of 0.3% methyl p-hydroxybenzoate and 0.1% propyl p-hydroxybenzoate.
一种阴道酸碱缓冲凝胶制备方法如下:A preparation method of vaginal acid-base buffer gel is as follows:
S1、称取适量枸橼酸钠,加入适量纯化水,搅拌溶解备用;S1. Weigh an appropriate amount of sodium citrate, add an appropriate amount of purified water, stir and dissolve for later use;
S2、按原料配比,将一半的纯化水注入乳化机组配料罐内,然后将纯化水加热至100℃进行灭菌30分钟,并冷确至80℃后,并按配比向乳化机组配料罐内依次加入司盘60、吐温80、聚卡波非、羟丙基甲基纤维素和白凡士林,采用均质机边搅拌边溶胀,时间为1小时;S2. According to the ratio of raw materials, inject half of the purified water into the emulsification unit batching tank, then heat the purified water to 100°C for sterilization for 30 minutes, and cool it to 80°C, and then send it to the emulsification unit batching tank according to the ratio Add Span 60, Tween 80, Polycarbophil, Hydroxypropyl Methyl Cellulose and White Vaseline in sequence, and swell while stirring with a homogenizer for 1 hour;
S3、按配比,按配比,向乳化机组配料罐内加入抑菌剂,搅拌30分钟;S3. According to the ratio, add the antibacterial agent to the batching tank of the emulsification unit and stir for 30 minutes;
S4、开启真空,开启冷却水,对乳化机组配料罐进行冷却,当温度降至45℃时,关闭冷却水;S4. Turn on the vacuum and turn on the cooling water to cool the batching tank of the emulsification unit. When the temperature drops to 45°C, turn off the cooling water;
S5、按配比,向乳化机组配料罐内加入配制好的0.6%浓度的枸橼酸钠溶液,按配比加纯化水至足量,采用均质机搅拌30分钟,制得本品。S5. According to the proportion, add the prepared 0.6% sodium citrate solution into the emulsification unit batching tank, add purified water according to the proportion to a sufficient amount, and stir with a homogenizer for 30 minutes to prepare this product.
实施例3:Example 3:
在实施例2基础上,一种阴道酸碱缓冲凝胶,包括以下质量组分的物质:油相基29%由组分白凡士林26%、1%的司盘60和2%的吐温80组成;On the basis of Example 2, a vaginal acid-base buffer gel, including the following mass components: oil phase base 29% composed of white petrolatum 26%, 1% Span 60 and 2% Tween 80 composition;
水相基70%由组分为1%的卡波姆、1%的聚卡波非、纯化水68%组成;70% of the water phase base is composed of 1% carbomer, 1% polycarbophil, and 68% purified water;
酸碱调节剂0.6%由0.3%枸橼酸钠和0.3%的氢氧化钠组成;The acid-base regulator 0.6% is composed of 0.3% sodium citrate and 0.3% sodium hydroxide;
抑菌剂0.4%由苯扎氯铵组成。The antibacterial agent 0.4% consists of benzalkonium chloride.
实验分析:experiment analysis:
阴道pH值失横,细菌就很容易入侵,导致各种阴道炎症的发生。阴道炎以细菌性阴道炎最为多见,患有细菌性阴道炎的女性,阴道酸碱度往往都大于6.0。那么在阴道酸碱缓冲凝胶的pH值设定上需要注意建立阴道环境的微平衡。pH值的设定需打破常规的中性,而 应选择中性偏酸性的一个酸碱值(4.0至5.5),这样的凝胶才能有效的调节原有炎症的阴道环境,去除阴道异味,改善阴道分泌物增多、瘙痒等症状;If the pH of the vagina is lost, bacteria can easily invade, leading to various vaginal inflammations. Vaginitis is most common with bacterial vaginitis. Women with bacterial vaginitis often have a vaginal pH greater than 6.0. In the setting of the pH value of the vaginal acid-base buffer gel, attention should be paid to establishing the micro-balance of the vaginal environment. The setting of pH value needs to break the conventional neutrality, and choose a pH value (4.0 to 5.5) that is neutral and acidic, so that the gel can effectively regulate the vaginal environment of the original inflammation, remove vaginal odor, and improve Symptoms such as increased vaginal discharge and itching;
在2018年1月至2018年6月,在公司内部收集到员工及家属共计198名患有妇科疾病(主要为阴道炎、瘙痒、白带异常等)的女性作为研究对象,随机分为A1组与B1组,A2组与B2组、A3组与B3组,每组各33人;From January 2018 to June 2018, a total of 198 women suffering from gynecological diseases (mainly vaginitis, pruritus, abnormal leucorrhea, etc.) from employees and their families were collected within the company as research subjects, and they were randomly divided into group A1 and group A1. Group B1, Group A2 and Group B2, Group A3 and Group B3, 33 people in each group;
其中,A1组、A2组和A3组按使用说明使用原处方产品阴道pH缓冲凝胶;B1组、B2组和B3组按使用说明分别使用实施例1、实施例2和实施例3处方优化后的阴道pH缓冲凝胶,连续使用相应药物,且每天各一次,用药14天后,其统计数据如下:Among them, the A1, A2, and A3 groups use the original prescription product vaginal pH buffer gel according to the instructions; the B1, B2 and B3 groups use the formulas of Example 1, Example 2, and Example 3 respectively according to the instructions. The vagina pH buffering gel, the corresponding drugs are used continuously, and once a day, 14 days after the drug, the statistics are as follows:
表1—使用实施例1制得的药物Table 1-Drugs prepared using Example 1
 To 治愈cure 显著Significant 有效effective 无效invalid 有效率(%)Efficient(%)
A1组Group A1 0人0 people 8人8 people 17人17 people 8人8 people 75.7%75.7%
B1组Group B1 1人1 person 9人9 people 17人17 people 6人6 people 81.8%81.8%
表2—使用实施例2制得的药物Table 2-Drugs prepared using Example 2
 To 治愈cure 显著Significant 有效effective 无效invalid 有效率(%)Efficient(%)
A2组Group A2 0人0 people 10人10 people 16人16 people 7人7 people 78.8%78.8%
B2组Group B2 2人2 people 11人11 people 18人18 people 2人2 people 94.0%94.0%
表3—使用实施例3制得的药物Table 3-Drugs prepared using Example 3
 To 治愈cure 显著Significant 有效effective 无效invalid 有效率(%)Efficient(%)
A3组Group A3 0人0 people 9人9 people 17人17 people 7人7 people 78.8%78.8%
B3组Group B3 0人0 people 11人11 people 17人17 people 5人5-people 84.8%84.8%
有上表数据可知:本方法制备的阴道pH缓冲凝胶效果优于原处方阴道pH缓冲凝胶,且实施例2制得的药物产品,可明显可以改善治疗效果;The data in the above table shows that the vaginal pH buffering gel prepared by this method has better effects than the original prescription vaginal pH buffering gel, and the drug product prepared in Example 2 can significantly improve the therapeutic effect;
以上仅为本发明的优选实施例而已,并不用于限制本发明,尽管参照前述实施例对本发明进行了详细的说明,对于本领域的技术人员来说,其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换。凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。The above are only the preferred embodiments of the present invention and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, for those skilled in the art, it is still possible to describe the foregoing various embodiments. Modify the technical solution or equivalently replace some of its technical features. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims (6)

  1. 一种阴道酸碱缓冲凝胶,其特征在于:由以下质量组分的物质组成,油相基1%至39%、水相基60%至99%、酸碱调节剂0.001%至2%和抑菌剂0.05%至5%;A vaginal acid-base buffer gel, which is characterized in that it is composed of the following mass components: oil phase base 1% to 39%, water phase base 60% to 99%, acid base regulator 0.001% to 2% and Bacteriostatic agent 0.05% to 5%;
    所述油相基组分为白凡士林、液体石蜡、山嵛酸甘油酯、司盘、吐温、甘油、丙二醇中一种或多种的混合物;The oil phase base component is a mixture of one or more of white petrolatum, liquid paraffin, glyceryl behenate, Span, Tween, glycerin, and propylene glycol;
    水相基组分为羟丙基甲基纤维素、卡波姆、羧甲基纤维素钠、聚卡波非、聚乙二醇、氮酮、明胶、纯化水中的一种或多种的混合物;The water-based components are one or more mixtures of hydroxypropyl methyl cellulose, carbomer, sodium carboxymethyl cellulose, polycarbophil, polyethylene glycol, azone, gelatin, and purified water ;
    酸碱调节剂为枸橼酸、枸橼酸钠、氢氧化钠、盐酸、三乙醇胺、硼酸、硼砂、磷酸二氢钠、磷酸氢二钠的一种或多种的混合物;The acid-base regulator is a mixture of one or more of citric acid, sodium citrate, sodium hydroxide, hydrochloric acid, triethanolamine, boric acid, borax, sodium dihydrogen phosphate, and disodium hydrogen phosphate;
    抑菌剂为苯甲酸、苯甲酸钠、苯甲醇、苯扎溴铵、苯扎氯铵、山梨酸、山梨酸钾、尼泊金类的一种或多种的混合物。The bacteriostatic agent is one or more mixtures of benzoic acid, sodium benzoate, benzyl alcohol, benzalkonium bromide, benzalkonium chloride, sorbic acid, potassium sorbate, and parabens.
  2. 根据权利要求1所述的一种阴道酸碱缓冲凝胶,其特征在于:油相基39%、水相基60%、酸碱调节剂0.6%和抑菌剂0.4%;A vaginal acid-base buffer gel according to claim 1, characterized in that: oil phase base 39%, water phase base 60%, acid-base regulator 0.6% and bacteriostatic agent 0.4%;
    所述油相基组分由白凡士林、司盘60和吐温80组成;The oil phase base component is composed of white petrolatum, Span 60 and Tween 80;
    水相基组分由羟丙基甲基纤维素和纯化水组成;The water phase base component is composed of hydroxypropyl methyl cellulose and purified water;
    酸碱调节剂由枸橼酸钠组成;Acid-base regulator is composed of sodium citrate;
    抑菌剂由对羟基苯甲酸甲酯、对羟基苯甲酸丙酯组成。The bacteriostatic agent is composed of methyl p-hydroxybenzoate and propyl p-hydroxybenzoate.
  3. 根据权利要求2所述的一种阴道酸碱缓冲凝胶,其特征在于:油相基39%由组分白凡士林36%、1%的司盘60和2%的吐温80组成;A vaginal acid-base buffer gel according to claim 2, wherein 39% of the oil phase base is composed of 36% white petrolatum, 1% Span 60 and 2% Tween 80;
    水相基60%由组分为1%的羟丙基甲基纤维素、1%的聚卡波非和纯化水58%组成;60% of the water phase base is composed of 1% hydroxypropyl methylcellulose, 1% polycarbophil and 58% purified water;
    酸碱调节剂0.6%由枸橼酸钠溶液组成;The acid-base regulator 0.6% is composed of sodium citrate solution;
    抑菌剂0.4%由对羟基苯甲酸甲酯0.3%和对羟基苯甲酸丙酯0.1%组成。The antibacterial agent 0.4% is composed of 0.3% methyl p-hydroxybenzoate and 0.1% propyl p-hydroxybenzoate.
  4. 一种阴道酸碱缓冲凝胶制备方法,其特征在于,其步骤如下:A method for preparing vaginal acid-base buffer gel, which is characterized in that the steps are as follows:
    S1、称取适量枸橼酸钠,加入适量纯化水,搅拌溶解备用;S1. Weigh an appropriate amount of sodium citrate, add an appropriate amount of purified water, stir and dissolve for later use;
    S2、按原料配比,将一半的纯化水注入乳化机组配料罐内,然后将纯化水加热至100℃进行灭菌,并冷确至80℃后,并按配比向乳化机组配料罐内依次加入白凡士林、司盘60、吐温80、聚卡波非和羟丙基甲基纤维素,边搅拌边溶胀,时间为1小时;S2. According to the ratio of raw materials, inject half of the purified water into the batching tank of the emulsification unit, then heat the purified water to 100°C for sterilization, and cool it to 80°C, and then add it to the batching tank of the emulsification unit according to the ratio. White Vaseline, Span 60, Tween 80, Polycarbophil and Hydroxypropyl Methyl Cellulose, swell while stirring, for 1 hour;
    S3、按配比,向乳化机组配料罐内加入抑菌剂,搅拌30分钟;S3. According to the ratio, add the antibacterial agent to the batching tank of the emulsification unit, and stir for 30 minutes;
    S4、开启真空,开启冷却水,对乳化机组配料罐进行冷却,当温度降至45℃时,关闭冷却水;S4. Turn on the vacuum and turn on the cooling water to cool the batching tank of the emulsification unit. When the temperature drops to 45°C, turn off the cooling water;
    S5、按配比,向乳化机组配料罐内加入配制好的枸橼酸钠溶液,按配比加纯化水至足量,搅拌30分钟,制得本品。S5. Add the prepared sodium citrate solution to the batching tank of the emulsification unit according to the ratio, add purified water to sufficient amount according to the ratio, and stir for 30 minutes to prepare this product.
  5. 根据权利要求4所述的一种阴道酸碱缓冲凝胶制备方法,其特征在于:S2步骤中,灭菌时间为30至60分钟。The method for preparing vaginal acid-base buffer gel according to claim 4, characterized in that: in step S2, the sterilization time is 30 to 60 minutes.
  6. 根据权利要求4所述的一种阴道酸碱缓冲凝胶制备方法,其特征在于:S3和S5步骤中,全部采用均质机进行混合搅拌。The method for preparing vaginal acid-base buffer gel according to claim 4, characterized in that in steps S3 and S5, a homogenizer is used for mixing and stirring.
PCT/CN2020/085844 2019-08-28 2020-04-21 Vaginal acid-base buffer gel and preparation method WO2021036294A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910803584.9A CN110575431B (en) 2019-08-28 2019-08-28 Vaginal acid-base buffer gel and preparation method thereof
CN201910803584.9 2019-08-28

Publications (1)

Publication Number Publication Date
WO2021036294A1 true WO2021036294A1 (en) 2021-03-04

Family

ID=68812198

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2020/085844 WO2021036294A1 (en) 2019-08-28 2020-04-21 Vaginal acid-base buffer gel and preparation method

Country Status (2)

Country Link
CN (1) CN110575431B (en)
WO (1) WO2021036294A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110575431B (en) * 2019-08-28 2021-08-03 南京天朗制药有限公司 Vaginal acid-base buffer gel and preparation method thereof
CN110882211A (en) * 2019-12-31 2020-03-17 深圳市瀚德标检生物工程有限公司 Hydroxyphenyl ester gel and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
CN102170860A (en) * 2008-08-14 2011-08-31 Incrementha医药研发创新有限公司 Mucoadherents compositions and their use
CN102688182A (en) * 2012-06-04 2012-09-26 王洪明 Vagina pH buffer antibacterial gel and preparation method thereof
CN106075446A (en) * 2016-06-24 2016-11-09 青岛中腾生物技术有限公司 A kind of slow release gynecological gel and preparation method thereof
CN108498876A (en) * 2018-05-06 2018-09-07 李志军 antibacterial lubricating gel
CN108853004A (en) * 2018-07-24 2018-11-23 株洲千金药业股份有限公司 A method of preparing metronidazole vagina gel
CN110269835A (en) * 2019-08-05 2019-09-24 江苏开源康达医疗器械有限公司 A kind of antibacterial prosthetic gel of carbomer gynaecology and preparation method thereof
CN110575431A (en) * 2019-08-28 2019-12-17 南京天朗制药有限公司 Vaginal acid-base buffer gel and preparation method thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276836A1 (en) * 1997-06-11 2005-12-15 Michelle Wilson Coated vaginal devices for vaginal delivery of therapeutically effective and/or health-promoting agents
CN102170860A (en) * 2008-08-14 2011-08-31 Incrementha医药研发创新有限公司 Mucoadherents compositions and their use
CN102688182A (en) * 2012-06-04 2012-09-26 王洪明 Vagina pH buffer antibacterial gel and preparation method thereof
CN106075446A (en) * 2016-06-24 2016-11-09 青岛中腾生物技术有限公司 A kind of slow release gynecological gel and preparation method thereof
CN108498876A (en) * 2018-05-06 2018-09-07 李志军 antibacterial lubricating gel
CN108853004A (en) * 2018-07-24 2018-11-23 株洲千金药业股份有限公司 A method of preparing metronidazole vagina gel
CN110269835A (en) * 2019-08-05 2019-09-24 江苏开源康达医疗器械有限公司 A kind of antibacterial prosthetic gel of carbomer gynaecology and preparation method thereof
CN110575431A (en) * 2019-08-28 2019-12-17 南京天朗制药有限公司 Vaginal acid-base buffer gel and preparation method thereof

Also Published As

Publication number Publication date
CN110575431B (en) 2021-08-03
CN110575431A (en) 2019-12-17

Similar Documents

Publication Publication Date Title
RU2408372C2 (en) Application of octenidine dihydrochloride in semisolid preparations
AU2010305200B2 (en) Composition comprising benzoic acid in combination with organic acid preservatives as active components and use thereof
EP1784176B1 (en) Composition comprising lactic acid and lactoferrin
WO2021036294A1 (en) Vaginal acid-base buffer gel and preparation method
CN108635585A (en) A kind of pharmaceutical composition for treating senile vahinitis and temperature sensitive slow-releasing gel used and preparation method
CN109674826A (en) A kind of probiotic composition for nursing female reproductive system
CN108420789B (en) Benzalkonium chloride solution for external use and preparation method thereof
CN113730433B (en) Gynecological gel for treating colpitis and preparation method and application thereof
AU2015292258A1 (en) Compositions and methods of use
CN103191408B (en) Medicine composition and gel for treating colpitis and applications thereof
CN107754011A (en) A kind of liquid dressing for treating hemorrhoid and preparation method thereof
US20180104346A1 (en) Vaginal Bioadhesive Boric Acid Formulation and Its Preparation Method
CN104706668A (en) Female care solution containing silver ions and preparation method of female care solution
CN112022902A (en) Preparation method and application of carbon-point modified fluconazole eucalyptus oil microemulsion gel
EP3501507A1 (en) Macrogols for application to the mucosa, and therapeutic uses thereof
CN115501328A (en) Sodium azulene sulfonate chitosan gel and preparation process thereof
CN106266037B (en) Liquid gel and preparation method thereof
CN103520091A (en) Acidic buffer temperature-sensitive gel preparation for vagina as well as preparation method and application thereof
CN113332278A (en) Isatin and dihydrocannabinol compound and medical application thereof
US20200093858A1 (en) Vaginal bioadhesive boric acid formulation and its preparation method
CN110876715A (en) Nasal cavity flushing fluid
CN113230205B (en) Gynecological gel preparation and preparation method and application thereof
CN110623915B (en) Butoconazole nitrate vaginal expansion suppository and preparation method and application thereof
CN103127490A (en) Medicinal composition for treating vulvovaginal candidiasis
WO2023231049A1 (en) Antibacterial dressing for promoting scarless healing of wounds and preparation method therefor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20856660

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20856660

Country of ref document: EP

Kind code of ref document: A1